Efficacy and safety of Efavirenz in HIV patients on Rifampin for tuberculosis

Efficacy and safety of Efavirenz in HIV patients on Rifampin for tuberculosis

Forty-nine AIDS patients, most of who were antiretroviral therapy (ARV) naïve, with active tuberculosis, were treated with Rifampin 600mg, Isoniazid 400mg and Pirazinamide 2g daily. They also received ARV, consisting of Efavirenz (600mg/day) plus 2 NRTIs. All patients were prospectively followed for...

Full description

Bibliographic Details
Main Authors:	Diana B. Pedral-Sampaio, Carmosina R. Alves, Eduardo M. Netto, Carlos Brites, Adriano S. Oliveira, Roberto Badaro
Format:	Article
Language:	English
Published:	Elsevier
Series:	Brazilian Journal of Infectious Diseases
Subjects:	Tuberculosis HIV/AIDS drug interaction Rifampin Efavirenz antiretroviral therapy
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702004000300004&lng=en&tlng=en

Similar Items

Effectiveness of reduced-dose efavirenz in hiv therapy considering patient adherence
by: Fors, John
Published: (2012)

Comparison of the effectiveness of initial combined antiretroviral therapy with nelfinavir or efavirenz at a university-based outpatient service in Brazil
by: T. Vanni, et al.
Published: (2007-07-01)

Nevirapine- versus Efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and Tuberculosis infections in India: a multi-centre study
by: Sanjeev Sinha, et al.
Published: (2017-12-01)

Efavirenz Plasma Concentrations and HIV Viral Load in HIV/AIDS-tuberculosis Infection Patients Treated with Rifampicin
by: Nina Mariana, et al.
Published: (2016-09-01)

Perbandingan Penggunaan Efavirenz dan Nevirapine Terhadap Kolesterol LDL Pasien HIV/AIDS
by: Anggriani Yusi, et al.
Published: (2019-08-01)

rpoB Mutations and Effects on Rifampin Resistance in Mycobacterium tuberculosis
by: Li M, et al.
Published: (2021-10-01)

Etymologia: Rifampin
by: Ronnie Henry
Published: (2018-03-01)

CYP2B6 516 G>T polymorphism and side effects of the central nervous system in HIV-positive individuals under Efavirenz treatment: Study of a sample from southern Brazil
by: TALISE E. MÜLLER, et al.

Development and validation of analytical method for quantitation of Emtricitabine, Tenofovir, Efavirenz based on HPLC
by: Arun Ramaswamy, et al.
Published: (2018-02-01)

The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in <it>Mycobacterium tuberculosis</it>
by: Parsons Linda M, et al.
Published: (2001-04-01)

Identifying Mycobacterium Tuberculosis Resistance to Rifampin by Multiplex Specific PCR Method
by: Masjedi M.R, et al.
Published: (2011-03-01)

Identifying Mycobacterium Tuberculosis Resistance to Rifampin by Multiplex Specific PCR Method
by: F Din Mohammadi, et al.
Published: (2011-04-01)

Identification of Mycobacterium tuberculosis and Rifampin Resistance in Pulmonary and Extra-pulmonary Clinical Specimens Using the Gene Xpert MTB/RIF Assay
by: Fahimeh Azadi, et al.
Published: (2021-07-01)

Mycobacterium tuberculosis and Rifampin Resistance, United Kingdom
by: I-Ching Sam, et al.
Published: (2006-05-01)

PXR and CAR single nucleotide polymorphisms influence plasma efavirenz levels in South African HIV/AIDS patients
by: Swart Marelize, et al.
Published: (2012-11-01)

Rifampin resistance among individuals with extrapulmonary tuberculosis: 4 years of experience from a reference laboratory
by: S. Baghbanbashi, et al.
Published: (2021-03-01)

Intestinal permeability and malabsorption of rifampin and isoniazid in active pulmonary tuberculosis
by: Valéria G. F. Pinheiro, et al.

Discordance in Mycobacterium tuberculosis Rifampin Susceptibility
by: Ameeta S. Kalokhe, et al.
Published: (2012-03-01)

Effects of vitamin D supplementation on the bone specific biomarkers in HIV infected individuals under treatment with efavirenz
by: Etminani-Esfahani Maryam, et al.
Published: (2012-04-01)

Gynecomastia in HIV-positive adult men receiving efavirenz-based antiretroviral therapy at Newlands clinic, Harare, Zimbabwe
by: Sandra Shawarira-Bote, et al.
Published: (2019-08-01)

Neuropsychiatric Adverse Events During 12 Months of Treatment With Efavirenz in Treatment-Naïve HIV-Infected Patients in China: A Prospective Cohort Study
by: Wei Hua, et al.
Published: (2021-02-01)

Pharmacokinetic interactions between rifampicin and efavirenz in HIV-TB coinfections
by: Yenny
Published: (2009-12-01)

Pharmacokinetic interactions between rifampicin and efavirenz in HIV-TB coinfections
by: Yenny Yenny
Published: (2016-02-01)

Evaluation of disease patterns, treatment and prognosis of tuberculosis in AIDS patient
by: Angela Naomi Atomiya, et al.

Evaluation of disease patterns, treatment and prognosis of tuberculosis in AIDS patient
by: Atomiya Angela Naomi, et al.
Published: (2002-01-01)

Economic modeling of the combined effects of HIV-disease, cholesterol and lipoatrophy based on ACTG 5142 trial data
by: Garren Kevin W, et al.
Published: (2011-05-01)

Investigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic Analysis
by: Nathan W. Cummins, et al.
Published: (2015-07-01)

Characterization of rifampin-resistant Staphylococcus aureus nasal carriage in patients receiving rifampin-containing regimens for tuberculosis
by: Huang YT, et al.
Published: (2018-08-01)

Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF)
by: Ruth Nabisere, et al.
Published: (2020-02-01)

Healthcare Provider Discrimination toward Pregnant Women with Rifampin-Resistant Tuberculosis
by: Marian Loveday, et al.
Published: (2019-03-01)

Avaliação biofarmacotécnica do Efavirenz um fármaco classe II (SCB)
by: César Galindo Bedor, Danilo
Published: (2014)

Molecular Identification of Mycobacterium tuberculosis and Analysis of Its Resistance to Rifampin in Sputa From Tuberculosis Suspected Patients
by: M. Syaifudin
Published: (2010-08-01)

Evaluation of GeneXpert Mycobacterium tuberculosis/Rifampin for the detection of Mycobacterium tuberculosis complex and rifampicin resistance in nonrespiratory clinical specimens
by: Maya Habous, et al.
Published: (2019-01-01)

Detection of rifampin-resistant genotypes in Mycobacterium tuberculosis by reverse hybridization assay
by: Raquel de A Maschmann, et al.
Published: (2011-03-01)

Efavirenz Loaded Nanostructured Lipid Carriers for Efficient and Prolonged Viral Inhibition in HIV-Infected Macrophages
by: Ketan Mahajan, et al.
Published: (2021-09-01)

Safety, strength and simplicity of efavirenz in pregnancy
by: Prinitha Pillay, et al.
Published: (2012-03-01)

An expanded analysis of pharmacogenetics determinants of efavirenz response that includes 3'-UTR single nucleotide polymorphisms among Black South African HIV/AIDS patients
by: Marelize eSwart, et al.
Published: (2016-01-01)

Neuropsychiatric Side Effects Associated with Efavirenz Therapy in HIV/AIDS Patients
by: Hayat KUMBASAR KARAOSMANOĞLU, et al.
Published: (2010-03-01)

Adsorption of antiretroviral drugs, efavirenz and nevirapine from aqueous solution by graphene wool: Kinetic, equilibrium, thermodynamic and computational studies
by: Adedapo O. Adeola, et al.
Published: (2021-12-01)

Serum Lipid Profiles of Patients Taking Efavirenz-Based Antiretroviral Regimen Compared to Ritonavir-Boosted Atazanavir with an Optimized Background at Zewditu Memorial Hospital, Addis Ababa, Ethiopia
by: Muche Belete A, et al.
Published: (2021-02-01)

Cannot write session to /tmp/vufind_sessions/sess_3cdd29o873qgcf02e8dom20ht6